Impact of APP-assisted Patient Management on the Quality Control of Blood Purification Therapy

NCT07291154 | Recruiting

• 1 other identifier: 1st ChongqingMedicalUniversity
• Study Type: interventional
• Target: 392
• Locations: 1 country
• Sites: 1

Brief Summary

Many maintenance hemodialysis (MHD) patients develop negative outlooks due to their illnesses and complications, making their quality of life and prognosis a clinical concern. Effective life management and treatment cooperation are crucial to improving dialysis quality and patient outcomes. This trial aims to evaluate whether management through the "Yueya" mini-program and WeChat can provide personalized guidance such as health education, diet, exercise, medication supervision, and condition monitoring to enhance treatment compliance, quality of life, strengthen quality control in the hemodialysis unit, and improve patient prognosis. Patients will be divided into a group receiving support via the "Yueya" mini-program and WeChat, and a control group receiving routine care. Clinical and laboratory indicators, cardiovascular events, death, hospitalization, quality of life, and compliance will be recorded and compared between groups to assess the impact of APP-assisted patient management on the quality of MHD blood purification therapy and the prognosis of MHD patients.

Conditions

End Stage Renal Disease (ESRD); Maintenance Hemodialysis

Outcome Measures

Primary Outcomes (4)

• mortality rate

  In this study, mortality rate was used as a prognostic indicator.

  About 1 year

• Hospitalization rate

  In this study, the hospitalization rate was used as a prognostic indicator.

  About 1 year

• Kidney Disease Quality of Life

  Measuring the quality of life of hemodialysis patients through the Kidney Disease Quality of Life-36（KDQOL-36） scale. If the KDQOL-36 score increases, the quality of life is considered to be improved.

  About 1 year

• Incidence of cardiovascular events

  About 1 year

Study Arms (2)

APP management group

EXPERIMENTAL

For the APP management group, according to the specific conditions of patients such as age, gender, primary disease and complications, the "Yueya" mini-program and WeChat will be used to provide individualized and all-weather guidance for dialysis patients in their daily lives, including health knowledge education, diet and exercise guidance, medication supervision, condition monitoring and real-time feedback.

Behavioral: APP-based management

Non-APP management group

NO INTERVENTION

For the non-APP management group, the APP mini-program will not be used to guide patients' daily lives, and only the previous routine management methods will be adopted.

Interventions

APP-based management BEHAVIORAL

Based on patients' specific conditions such as age, gender, primary disease, and complications, the APP-based management will provide individualized and round-the-clock guidance for dialysis patients in their daily lives through the "Yueya" mini-program and WeChat. This guidance covers various aspects, including health knowledge education, diet and exercise guidance, medication supervision, condition monitoring, and real-time feedback.

APP management group

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients with stage 5 chronic kidney disease, who have received maintenance hemodialysis for more than 3 months, are aged between 18 and 75 years old, and have regular dialysis three times a week.
• Patients with relatively stable condition, who are able to take care of themselves and willing to cooperate with the study.
• Patients who can understand and proficiently use WeChat and the "Yueya" mini - program used in this study.

You may not qualify if:

• Patients with communication barriers or other conditions that prevent them from cooperating with the study.
• Patients who have a history of acute myocardial infarction, cerebral infarction or intracerebral hemorrhage in the past six months.
• Patients who are not willing to actively cooperate with the study.
• Patients with severe liver cirrhosis, active tuberculosis and AIDS.

Sponsors & Collaborators

• Yunfeng Xia: lead

Study Sites (1)

The First Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, 400016, China

RECRUITING

MeSH Terms

Conditions

Kidney Failure, Chronic

Condition Hierarchy (Ancestors)

Renal Insufficiency, Chronic; Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Yunfeng Xia Dr

CONTACT

86-023-89012687; yunfengxia0920@126.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Cheif physician

Study Record Dates

• First Submitted: September 18, 2025
• First Posted: December 18, 2025
• Study Start: September 22, 2025
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2026
• Last Updated: December 18, 2025

Record last verified: 2025-10

Locations

CN (1)